We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Aripiprazole: in the treatment of irritability associated with autistic disorder in pediatric patients.
- Authors
Curran, Monique P
- Abstract
Aripiprazole is an atypical antipsychotic approved for the treatment of irritability associated with autistic disorder in pediatric patients aged 6-17 years. In two, randomized, double-blind, placebo-controlled studies in pediatric patients aged 6-17 years with irritability associated with autistic disorder, 8 weeks of treatment with aripiprazole 2-15 mg/day, compared with placebo, resulted in significant improvements in the Aberrant Behavior Checklist Irritability subscale score at endpoint (primary endpoint), and the mean Clinical Global Impression-Improvement score. Aripiprazole was generally well tolerated in this patient population in the two 8-week studies and a 52-week study, with most adverse events being mild to moderate in severity. Aripiprazole was associated with weight gain in both the short- and long-term studies; data from the long-term study indicated that the increase in bodyweight reached a plateau at 3-6 months.
- Publication
Paediatric drugs, 2011, Vol 13, Issue 3, p197
- ISSN
1179-2019
- Publication type
Journal Article
- DOI
10.2165/11207230-000000000-00000